{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T22:33:42Z","timestamp":1781476422951,"version":"3.54.1"},"reference-count":323,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ITT"],"DOI":"10.2147\/itt.s306103","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T12:30:07Z","timestamp":1631104207000},"page":"343-371","source":"Crossref","is-referenced-by-count":18,"title":["Immunotherapy of Multiple Myeloma: Promise and Challenges"],"prefix":"10.2147","volume":"Volume 10","author":[{"given":"Hanley N","family":"Abramson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","volume":"3","author":"Ailawadhi","year":"2019","journal-title":"Blood Advances"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/17474086.2021.1875815","volume":"14","author":"Yavorkovsky","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","volume":"18","author":"Kumar","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11899-017-0368-z","volume":"12","author":"Chan","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3390\/jcm10091841","volume":"10","author":"Poczta","year":"2021","journal-title":"J Clin Med"},{"key":"ref10","unstructured":"Myeloma - Cancer stat facts; 2021. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed August 27, 2021."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"8039","DOI":"10.1200\/JCO.2019.37.15_suppl.8039","volume":"37","author":"Nandakumar","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/17474086.2021.1909469","volume":"14","author":"Braunstein","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.3747\/co.27.5223","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"109821","DOI":"10.1016\/j.biopha.2020.109821","volume":"124","author":"Tan","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1080\/13543784.2020.181425","volume":"29","author":"Jiao","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4049\/jimmunol.160.1.395","volume":"160","author":"Deaglio","year":"1998","journal-title":"J Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"30327","DOI":"10.1074\/jbc.270.51.30327","volume":"270","author":"Aarhus","year":"1995","journal-title":"J Biol Chem"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1158\/1078-0432.ccr-14-3190","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.imlet.2018.04.005","volume":"199","author":"van de Donk","year":"2018","journal-title":"Immunol Lett"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0140-6736(19)31240-1","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/ajh.25963","volume":"95","author":"Durie","year":"2020","journal-title":"Am J Hematol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/s0140-6736(20)30734-0","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"ref27","unstructured":"Janssen Pharmaceutical Co. U.S. FDA approves new DARZALEX\u00ae (daratumumab)-based combination regimen for patients with relapsed\/refractory multiple myeloma [press release]. Horsham, PA; 2020. Available from:https:\/\/www.prnewswire.com\/news-releases\/us-fda-approves-new-darzalex-daratumumab-based-combination-regimen-for-patients-with-relapsedrefractory-multiple-myeloma-301116063.html. Accessed June 30, 2021."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/17474086.2020.1740084","volume":"13","author":"Musto","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2040620720987075","DOI":"10.1177\/2040620720987075","volume":"12","author":"Sanchez","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1182\/blood.2019000667","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"ref31","unstructured":"U.S. Food and Drug Administration. FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma [press release]. Washington, DC; 2020. Available from:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-daratumumab-and-hyaluronidase-fihj-multiple-myeloma. Accessed July 29, 2020."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1200\/jop.18.00143","volume":"14","author":"Nooka","year":"2018","journal-title":"J Oncol Pract"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/trf.13069","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1182\/blood.V128.22.2138.2138","volume":"128","author":"Boyle","year":"2016","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e874","DOI":"10.1016\/s2352-3026(20)30356-2","volume":"7","author":"Roussel","year":"2020","journal-title":"Lancet Haematol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1007\/s12325-020-01601-w","volume":"38","author":"Chari","year":"2021","journal-title":"Adv Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1080\/10428194.2020.1832672","volume":"62","author":"Leleu","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"LBA","DOI":"10.1182\/blood-2019-132629","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-020-00948-5","volume":"13","author":"Weisel","year":"2020","journal-title":"J Hematol Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8062","volume":"36","author":"Rajkumar","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194282","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/bjh.17435","volume":"194","author":"Plesner","year":"2021","journal-title":"Br J Haematol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8059","volume":"36","author":"Sonneveld","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/jco.20.01370","volume":"39","author":"Perrot","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00432-020-03365-w","volume":"147","author":"Usmani","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00277-021-04405-2","volume":"100","author":"Iida","year":"2021","journal-title":"Ann Hematol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e559","DOI":"10.1016\/s2352-3026(20)30188-5","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1158\/1078-0432.Ccr-18-1597","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40265-020-01311-1","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/s0140-6736(19)32556-5","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1053\/j.seminoncol.2020.04.004","volume":"47","author":"Richter","year":"2020","journal-title":"Semin Oncol"},{"key":"ref53","unstructured":"U.S. Food and Drug Administration. FDA approves isatuximab-irfc for multiple myeloma [press release]. Washington, DC; 2021. Available from:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-isatuximab-irfc-multiple-myeloma. Accessed April 15, 2021."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.2217\/fon-2019-0431","volume":"16","author":"Moreau","year":"2020","journal-title":"Future Oncol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-137681","volume":"136","author":"Martin","year":"2020","journal-title":"Blood"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"106576","DOI":"10.1016\/j.leukres.2021.106576","volume":"104","author":"Bringhen","year":"2021","journal-title":"Leuk Res"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2217\/fon-2017-0616","volume":"14","author":"Richardson","year":"2018","journal-title":"Future Oncol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"TPS8057","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8057","volume":"35 Supplement 15","author":"Richardson","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/bjh.17499","volume":"184","author":"Harrison","year":"2021","journal-title":"Br J Haematol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"8014","DOI":"10.1200\/JCO.2018.36.15_suppl","volume":"36","author":"Chari","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1182\/blood-2020-139358","volume":"136","author":"Thai","year":"2020","journal-title":"Blood"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1182\/blood-2019-123205","volume":"134","author":"Manasanch","year":"2019","journal-title":"Blood"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood.V128.22.2111.2111","volume":"128","author":"Martin III","year":"2016","journal-title":"Blood"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"TPS8055","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS805","volume":"36 Supplement 15","author":"Orlowski","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1182\/blood.V126.23.509.509","volume":"126","author":"Martin","year":"2015","journal-title":"Blood"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"8038","DOI":"10.1200\/JCO.2018.36.15_suppl.8038","volume":"35","author":"Mikhael","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"8038","DOI":"10.1200\/JCO.2018.36.15_suppl.8038","volume":"36","author":"Mikhael","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1182\/blood-2019-02-895193","volume":"134","author":"Mikhael","year":"2019","journal-title":"Blood"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01262-w","author":"Usmani","year":"2021","journal-title":"Leukemia"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.2217\/fon-2020-1088","volume":"17","author":"Grosicki","year":"2021","journal-title":"Future Oncol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/14740338.2017.1279603","volume":"16","author":"Gavriatopoulou","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.ccr-07-4246","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40265-016-0540-0","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1002\/cncr.31680","volume":"124","author":"Dimopoulos","year":"2018","journal-title":"Cancer"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.2147\/ott.S174640","volume":"12","author":"Trudel","year":"2019","journal-title":"Onco Targets Ther"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/s2352-3026(20)30354-9","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/jco.2011.37.7069","volume":"30","author":"Jakubowiak","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2020-138447","volume":"136","author":"Silvennoinen","year":"2020","journal-title":"Blood"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1200\/JCO.2018.36.15_suppl.8012","volume":"36","author":"Yee","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ajh.24687","volume":"92","author":"Berenson","year":"2017","journal-title":"Am J Hematol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/bjh.15384","volume":"182","author":"Jagannath","year":"2018","journal-title":"Br J Haematol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s00280-016-3182-8","volume":"78","author":"Passey","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1186\/s12885-019-5600-x","volume":"19","author":"Salwender","year":"2019","journal-title":"BMC Cancer"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.1200\/JCO.2020.38.15_suppl.8507","volume":"38 Supplement 15","author":"Usmani","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1208\/s12248-016-0033-9","volume":"19","author":"Passey","year":"2017","journal-title":"Aaps j"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"e2018014","DOI":"10.4084\/mjhid.2018.014","volume":"10","author":"Taniwaki","year":"2018","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjh.14787","volume":"178","author":"Dimopoulos","year":"2017","journal-title":"Br J Haematol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1016\/s2352-3026(15)00197-0","volume":"2","author":"Richardson","year":"2015","journal-title":"Lancet Haematol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"8052","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8052","volume":"35","author":"Lonial","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/19420862.2018.1466767","volume":"10","author":"Pereira","year":"2018","journal-title":"mAbs"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.3892\/ol.2017.6528","volume":"14","author":"Pan","year":"2017","journal-title":"Oncol Lett"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/bjh.14483","volume":"176","author":"Raje","year":"2017","journal-title":"Br J Haematol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/sj.bjc.6605241","volume":"101","author":"Rossi","year":"2009","journal-title":"Br J Cancer"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/nar\/22.7.1147","volume":"22","author":"Laabi","year":"1994","journal-title":"Nucleic Acids Res"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood.V81.2.454.454","volume":"81","author":"Kozlow","year":"1993","journal-title":"Blood"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"735","DOI":"10.4049\/jimmunol.149.2.735","volume":"149","author":"Zhou","year":"1992","journal-title":"J Immunol"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1002\/j.1460-2075.1992.tb05482.x","volume":"11","author":"Laabi","year":"1992","journal-title":"EMBO J"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3390\/cancers12061473","volume":"12","author":"Cho","year":"2020","journal-title":"Cancers"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40779-021-00302-x","volume":"8","author":"Fang","year":"2021","journal-title":"Mil Med Res"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/14737159.2018.1448269","volume":"18","author":"Sanchez","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1158\/1078-0432.Ccr-15-2224","volume":"22","author":"Sanchez","year":"2016","journal-title":"Clin Cancer Res"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/curroncol28010063","volume":"28","author":"Lassiter","year":"2021","journal-title":"Curr Oncol"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/imt.15.77","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref118","unstructured":"U.S. Food and Drug Administration. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma [press release]. Washington, DC; 2020. Available from:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma. Accessed May 5, 2021."},{"key":"ref119","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s1470-2045(19)30788-0","volume":"21","author":"Lonial","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","volume":"35","author":"Lee","year":"2020","journal-title":"Leukemia"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/ph13090245","volume":"13","author":"Joubert","year":"2020","journal-title":"Pharmaceuticals"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ddtec.2018.08.005","volume":"30","author":"Pahl","year":"2018","journal-title":"Drug Discov Today Technol"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"LB","DOI":"10.1158\/1538-7445.Am2019-lb-106","volume":"79","author":"Spycher","year":"2019","journal-title":"Cancer Res"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1158\/1535-7163.Mct-20-0287","volume":"20","author":"Figueroa-Vazquez","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"ref127","unstructured":"Heidelberg Pharma AG FDA allows Heidelberg Pharma to start a phase I\/IIa clinical trial with ATAC candidate HDP-101 [press release]. Ladenburg, Germany; 2021. Available from:https:\/\/pipelinereview.com\/index.php\/2021020477353\/Antibodies\/FDA-Allows-Heidelberg-Pharma-to-Start-A-Phase-I\/IIa-Clinical-Trial-with-ATAC-Candidate-HDP-101.html. Accessed: June 25, 2021."},{"key":"ref128","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1182\/blood.V130.Suppl_1.741.741","volume":"130","author":"Trudel","year":"2017","journal-title":"Blood"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"e20527","DOI":"10.1200\/JCO.2020.38.15_suppl.e20527","volume":"38 Supplement 15","author":"Popat","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41408-020-00369-0","volume":"10","author":"Richardson","year":"2020","journal-title":"Blood Cancer J"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1182\/blood-2019-129893","volume":"134 Supplement 1","author":"Weisel","year":"2019","journal-title":"Blood"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"V447","DOI":"10.1093\/annonc\/mdz251.039","volume":"30 Supplement 5","author":"Trudel","year":"2019","journal-title":"Ann Oncol"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.1200\/JCO.2020.38.15_suppl.8502","volume":"38 Supplement 15","author":"Nooka","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-139332","volume":"136","author":"Popat","year":"2020","journal-title":"Blood"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2020-139181","volume":"136","author":"Rifkin","year":"2020","journal-title":"Blood"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-139785","volume":"136","author":"Trudel","year":"2020","journal-title":"Blood"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"TPS8556","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8556","volume":"38","author":"Usmani","year":"2020","journal-title":"J Clinical Oncol"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/0003-9861(61)90296-x","volume":"93","author":"Nisonoff","year":"1961","journal-title":"Arch Biochem Biophys"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1007\/s00432-020-03404-6","volume":"146","author":"Huang","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","volume":"65","author":"Rader","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/antib8030043","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcdb.2017.07.033","volume":"72","author":"Spicer","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nri3839","volume":"15","author":"Voskoboinik","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/0008-5472.Can-09-0547","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1158\/1535-7163.Mct-17-0657","volume":"17","author":"Mandikian","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"40098","DOI":"10.1038\/srep40098","volume":"7","author":"Mazor","year":"2017","journal-title":"Sci Rep"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/bjc.1998.518","volume":"78","author":"Velders","year":"1998","journal-title":"Br J Cancer"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.Ccr-18-2337","volume":"25","author":"Jen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40265-015-0356-3","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/0-387-24180-9_16","volume":"560","author":"Haas","year":"2005","journal-title":"Adv Exp Med Biol"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1038\/s41467-019-10948-w","volume":"10","author":"Nerreter","year":"2019","journal-title":"Nat Commun"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.3390\/ijms21155192","volume":"21","author":"Abramson","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","volume":"11","author":"Caraccio","year":"2020","journal-title":"Front Immunol"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2021.1872540","author":"Martino","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"2040620721989585","DOI":"10.1177\/2040620721989585","volume":"12","author":"Sanchez","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/jco.19.02657","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Advances"},{"key":"ref159","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2020-134063","volume":"136 Supplement 1","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"ref160","unstructured":"Amgen Inc. Amgen reports fourth quarter and full year 2020 financial results [press release]. Thousand Oaks, CA; 2021. Available from:https:\/\/investors.amgen.com\/news-releases\/news-release-details\/amgen-reports-fourth-quarter-and-full-year-2020-financial\/. Accessed May 21, 2021."},{"key":"ref161","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1182\/hematology.2020000110","volume":"2020","author":"Lancman","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref162","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1182\/blood-2019-126818","volume":"134","author":"Cooper","year":"2019","journal-title":"Blood"},{"key":"ref163","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","volume":"5","author":"DiLillo","year":"2021","journal-title":"Blood Advances"},{"key":"ref164","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1182\/blood.V128.22.5668.5668","volume":"128","author":"Girgis","year":"2016","journal-title":"Blood"},{"key":"ref165","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Advances"},{"key":"ref166","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-138831","volume":"136","author":"Garfall","year":"2020","journal-title":"Blood"},{"key":"ref167","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1200\/JCO.2020.38.15_suppl.100","volume":"38","author":"Usmani","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref168","doi-asserted-by":"publisher","first-page":"8007","DOI":"10.1200\/JCO.2021.39.15_suppl.8007","volume":"39","author":"Krishnan","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref169","doi-asserted-by":"publisher","first-page":"17253","DOI":"10.1038\/s41598-018-35489-y","volume":"8","author":"Suzuki","year":"2018","journal-title":"Sci Rep"},{"key":"ref170","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1182\/blood-2018-99-110427","volume":"132 Supplement 1","author":"Lesokhin","year":"2018","journal-title":"Blood"},{"key":"ref171","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1182\/blood-2019-121805","volume":"128","author":"Raje","year":"2019","journal-title":"Blood"},{"key":"ref172","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1182\/blood-2020-133355","volume":"136 Supplement 1","author":"Lesokhin","year":"2020","journal-title":"Blood"},{"key":"ref173","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.1200\/JCO.2021.39.15_suppl.8006","volume":"39 15 suppl","author":"Bahlis","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref174","unstructured":"Pfizer, Inc. Pfizer initiates pivotal phase 2 MAGNETISMM-3 trial of BCMA-CD3 bispecific antibody elranatamab (PF-06863135) in multiple myeloma [press release]. New York, NY; 2021. Available from:https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-initiates-pivotal-phase-2-magnetismm-3-trial-bcma. Accessed May 24, 2021."},{"key":"ref175","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/blood-2019-122895","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"ref176","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","volume":"11","author":"Trinklein","year":"2019","journal-title":"mAbs"},{"key":"ref177","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/jha2.69","volume":"1","author":"Foureau","year":"2020","journal-title":"eJHaem"},{"key":"ref178","doi-asserted-by":"publisher","first-page":"8034","DOI":"10.1200\/JCO.2018.36.15_suppl.8034","volume":"36","author":"Buelow","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref179","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1182\/blood-2019-123220","author":"Buelow","year":"2019","journal-title":"Blood"},{"key":"ref180","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2020-139893","volume":"136 Supplement 1","author":"Rodriguez","year":"2020","journal-title":"Blood"},{"key":"ref181","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2018-99-113921","volume":"132","author":"Law","year":"2018","journal-title":"Blood"},{"key":"ref182","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1182\/blood-2020-136012","volume":"136","author":"Schade","year":"2020","journal-title":"Blood"},{"key":"ref183","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.molimm.2004.07.034","volume":"42","author":"Smyth","year":"2005","journal-title":"Mol Immunol"},{"key":"ref184","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cpt.1396","volume":"106","author":"Duell","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"ref185","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1182\/blood.V128.22.4513.4513","volume":"128","author":"Gantke","year":"2016","journal-title":"Blood"},{"key":"ref186","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1158\/1538-7445.Am2020-4556","volume":"80","author":"Kakiuchi-Kiyota","year":"2020","journal-title":"Cancer Res"},{"key":"ref187","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.1158\/1538-7445.AM2019-4972","volume":"79","author":"Draghi","year":"2019","journal-title":"Cancer Res"},{"key":"ref188","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1182\/blood-2019-128749","volume":"134","author":"Watkins-Yoon","year":"2019","journal-title":"Blood"},{"key":"ref189","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"ref190","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2020-136985","volume":"136 Supplement 1","author":"Cohen","year":"2020","journal-title":"Blood"},{"key":"ref191","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood-2020-136980","volume":"136 Supplement 1","author":"Nakamura","year":"2020","journal-title":"Blood"},{"key":"ref192","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3132","volume":"36","author":"Richter","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref193","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1182\/blood.V122.21.139.139","volume":"122","author":"Lum","year":"2013","journal-title":"Blood"},{"key":"ref194","doi-asserted-by":"publisher","first-page":"S259","DOI":"10.1016\/j.bbmt.2011.12.162","volume":"18","author":"Lum","year":"2012","journal-title":"Biology Blood Marrow Transplantation"},{"key":"ref195","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Advances"},{"key":"ref196","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-133873","volume":"136","author":"Chari","year":"2020","journal-title":"Blood"},{"key":"ref197","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1535-7163.Mct-18-1216","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"ref198","doi-asserted-by":"publisher","first-page":"8007","DOI":"10.1200\/JCO.2019.37.15_suppl.8007","volume":"37","author":"Topp","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref199","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.clml.2019.09.082","volume":"19","author":"Cho","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref200","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood-2020-139192","volume":"136 Supplement 1","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"ref201","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.3747\/co.27.5283","volume":"27","author":"Wall","year":"2020","journal-title":"Curr Oncol"},{"key":"ref202","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMp1711886","volume":"377","author":"Rosenbaum","year":"2017","journal-title":"N Engl J Med"},{"key":"ref203","doi-asserted-by":"publisher","first-page":"e120505","DOI":"10.1172\/jci.insight.120505","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"ref204","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"ref205","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s1470-2045(18)30864-7","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref206","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"ref207","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","volume":"36","author":"Abramson","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref208","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ncponc0666","volume":"3","author":"Muranski","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"ref209","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"ref210","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1016\/S0021-9258(17)30447-7","volume":"253","author":"Shimizu","year":"1978","journal-title":"J Biol Chem"},{"key":"ref212","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"ref213","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1158\/1535-7163.Mct-20-0251","volume":"20","author":"Balog","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"ref214","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/s2352-3026(21)00057-0","volume":"8","author":"van de Donk","year":"2021","journal-title":"Lancet Haematol"},{"key":"ref215","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"ref216","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/jco.2018.77.8084","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref217","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/hum.2018.001","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"key":"ref218","unstructured":"U.S. Food and Drug Administration. FDA approves idecabtagene vicleucel for multiple myeloma [press release]. Washington, DC; 2021. Available from:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma. Accessed April 15, 2021."},{"key":"ref219","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"ref220","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","volume":"32","author":"Zheng","year":"2018","journal-title":"Leukemia"},{"key":"ref221","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood-2019-126660","author":"Berdeja","year":"2019","journal-title":"Blood"},{"key":"ref222","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood-2020-140410","volume":"136 Supplement 1","author":"Alsina","year":"2020","journal-title":"Blood"},{"key":"ref223","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref224","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"ref225","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood-2018-99-110548","volume":"132 Supplement 1","author":"Zhao","year":"2018","journal-title":"Blood"},{"key":"ref226","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2020-136307","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"ref227","unstructured":"Legend Biotech Corp. U.S. Food and Drug Administration grants BCMA CAR-T cilta-cel priority review for the treatment for relapsed\/refractory multiple myeloma [press release]. Somerset, NJ; 2021. Available from:https:\/\/www.businesswire.com\/news\/home\/20210526006114\/en\/U.S.-Food-and-Drug-Administration-Grants-BCMA-CAR-T-Cilta-cel-Priority-Review-for-the-Treatment-for-RelapsedRefractory-Multiple-Myeloma. Accessed June 4, 2021."},{"key":"ref228","doi-asserted-by":"publisher","first-page":"8013","DOI":"10.1200\/JCO.2021.39.15_suppl.8013","volume":"39","author":"Agha","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref229","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/protein\/gzw054","volume":"29","author":"Goldberg","year":"2016","journal-title":"Protein Eng Des Sel"},{"key":"ref230","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat Med"},{"key":"ref231","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","volume":"29","author":"Amatya","year":"2020","journal-title":"Mol Ther"},{"key":"ref232","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2020-142695","volume":"136 Supplement 1","author":"Costello","year":"2020","journal-title":"Blood"},{"key":"ref233","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","volume":"132 Supplement 1","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"ref234","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1182\/blood-2020-136748","volume":"136 Supplement 1","author":"Colonna","year":"2020","journal-title":"Blood"},{"key":"ref235","doi-asserted-by":"publisher","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","volume":"38","author":"Mailankody","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref236","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1182\/blood-2018-99-113220","volume":"132","author":"Jiang","year":"2018","journal-title":"Blood"},{"key":"ref237","unstructured":"CARSgen Therapeutics Co. Ltd. CARsgen announces investigational CAR-T therapy CT053 granted RMAT designation by the U.S. FDA for R\/R multiple myeloma [press release]. Shanghai, 2019. Available from:https:\/\/www.prnewswire.com\/news-releases\/carsgen-announces-investigational-car-t-therapy-ct053-granted-rmat-designation-by-the-us-fda-for-rr-multiple-myeloma-300945966.html. Accessed June 28, 2021."},{"key":"ref238","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2020-139802","volume":"136 Supplement 1","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"ref239","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"ref240","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/BS9.0000000000000068","volume":"3","author":"Xu","year":"2021","journal-title":"Blood Science"},{"key":"ref241","doi-asserted-by":"publisher","first-page":"8015","DOI":"10.1200\/JCO.2021.39.15_suppl.8015","volume":"1","author":"Frigault","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref242","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2020-138734","volume":"136 Supplement 1","author":"An","year":"2020","journal-title":"Blood"},{"key":"ref243","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","volume":"11","author":"Lam","year":"2020","journal-title":"Nat Commun"},{"key":"ref244","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2020-138839","volume":"136","author":"Mikkilineni","year":"2020","journal-title":"Blood"},{"key":"ref245","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","volume":"11","author":"Zah","year":"2020","journal-title":"Nat Commun"},{"key":"ref246","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3389\/fimmu.2019.01613","volume":"10","author":"Timmers","year":"2019","journal-title":"Front Immunol"},{"key":"ref247","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/coc.0000000000000669","volume":"43","author":"Jindal","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"ref248","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1631\/jzus.B1900351","volume":"21","author":"Huang","year":"2020","journal-title":"J Zhejiang Univ Sci B"},{"key":"ref249","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1182\/blood-2019-130340","volume":"134 Supplement 1","author":"Li","year":"2019","journal-title":"Blood"},{"key":"ref250","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3389\/fonc.2020.01362","volume":"10","author":"van der Schans","year":"2020","journal-title":"Front Oncol"},{"key":"ref251","doi-asserted-by":"publisher","first-page":"300060519893496","DOI":"10.1177\/0300060519893496","volume":"48","author":"Tang","year":"2020","journal-title":"J Int Med Res"},{"key":"ref252","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cam4.3624","volume":"10","author":"Yan","year":"2021","journal-title":"Cancer Med"},{"key":"ref253","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood-2020-138614","volume":"136 Supplement 1","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"ref254","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00254-w","author":"Prommersberger","year":"2021","journal-title":"Gene Ther"},{"key":"ref255","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.Ccr-17-0344","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"ref256","doi-asserted-by":"publisher","first-page":"101141","DOI":"10.1016\/j.beha.2020.101141","volume":"33","author":"Shah","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref257","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3389\/fonc.2020.01243","volume":"10","author":"Rodr\u00edguez-Lobato","year":"2020","journal-title":"Front Oncol"},{"key":"ref258","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-021-02277-x","volume":"12","author":"Lamb","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"ref259","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/hemato2020010","volume":"2","author":"Rubio","year":"2021","journal-title":"hemato"},{"key":"ref260","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"ref261","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/leu.2013.279","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"ref262","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol Oncol"},{"key":"ref263","doi-asserted-by":"publisher","first-page":"5100","DOI":"10.1038\/s41467-019-13088-3","volume":"10","author":"Sachdeva","year":"2019","journal-title":"Nat Commun"},{"key":"ref264","doi-asserted-by":"publisher","first-page":"E24","DOI":"10.1016\/j.clml.2019.09.035","volume":"19","author":"Sommer","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref265","unstructured":"Allogene Therapeutics, Inc. Allogene Therapeutics announces FDA Regenerative Medicine Advanced Therapy (RMAT) designation granted to ALLO-715, an AlloCAR T\u2122 cell therapy in development for relapsed\/refractory multiple myeloma [press release]. South San Francisco, CA, 2021. Available from:https:\/\/www.globenewswire.com\/news-release\/2021\/04\/21\/2214140\/0\/en\/Allogene-Therapeutics-Announces-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-Granted-to-ALLO-715-an-AlloCAR-T-Cell-Therapy-in-Development-for-Relapsed-Refractory-Mul.html. Accessed June 10, 2021."},{"key":"ref266","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood-2020-140641","volume":"1","author":"Mailankody","year":"2020","journal-title":"Blood"},{"key":"ref267","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.2021.39.15_suppl.2527","volume":"39","author":"Tees","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref268","doi-asserted-by":"publisher","first-page":"10286","DOI":"10.1038\/s41598-018-28599-0","volume":"8","author":"Prieto","year":"2018","journal-title":"Sci Rep"},{"key":"ref269","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/s1097-2765(00)80146-x","volume":"2","author":"Jurica","year":"1998","journal-title":"Mol Cell"},{"key":"ref270","unstructured":"Precision Biosciences, Inc. Precision BioSciences receives fast track designation from U.S. Food and Drug Administration for PBCAR269A, an investigational allogeneic CAR T therapy for relapsed\/refractory multiple myeloma [press release]. Durham, NC, 2020. Available from:https:\/\/investor.precisionbiosciences.com\/news-releases\/news-release-details\/precision-biosciences-receives-fast-track-designation-us-food. Accessed June 11, 2021."},{"key":"ref271","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"key":"ref272","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13256-020-02598-0","volume":"15","author":"Madduri","year":"2021","journal-title":"J Med Case Rep"},{"key":"ref273","doi-asserted-by":"publisher","first-page":"8030","DOI":"10.1200\/JCO.2021.39.15_suppl.8030","volume":"39","author":"Costa","year":"2021","journal-title":"Blood"},{"key":"ref274","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/antib8030041","volume":"8","author":"Strohl","year":"2019","journal-title":"Antibodies"},{"key":"ref275","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref276","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"ref277","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/16078454.2018.1549802","volume":"24","author":"Yu","year":"2019","journal-title":"Hematology"},{"key":"ref278","doi-asserted-by":"publisher","first-page":"E334","DOI":"10.1016\/j.clml.2020.12.010","volume":"21","author":"Aamir","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref279","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","volume":"6","author":"Wang","year":"2018","journal-title":"Biomarker Research"},{"key":"ref280","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1182\/blood-2004-08-2997","volume":"105","author":"Billiau","year":"2005","journal-title":"Blood"},{"key":"ref281","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/s0140-6736(20)30628-0","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"ref282","doi-asserted-by":"publisher","first-page":"108448","DOI":"10.1016\/j.clim.2020.108448","volume":"215","author":"Felsenstein","year":"2020","journal-title":"Clin Immunol"},{"key":"ref283","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10067-020-05190-5","author":"Soy","year":"2020","journal-title":"Clin Rheumatol"},{"key":"ref284","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/jci137244","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"ref285","unstructured":"U.S. Food and Drug Administration. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome [press release]. Washington, DC, 2017. Available from:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome. Accessed June 26, 2021."},{"key":"ref286","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2595","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"ref287","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2147\/tcrm.S223468","volume":"16","author":"Si","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"ref288","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","volume":"146","author":"Freyer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"ref289","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.Cd-17-1319","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"ref290","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.Cd-17-0698","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"ref291","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","volume":"18","author":"Yu","year":"2019","journal-title":"Mol Cancer"},{"key":"ref292","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3324\/haematol.2008.001677","volume":"94","author":"Griffioen","year":"2009","journal-title":"Haematologica"},{"key":"ref293","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1182\/blood-2018-99-112786","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"ref294","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1182\/blood-2019-127608","volume":"134 Supplement 1","author":"Fu","year":"2019","journal-title":"Blood"},{"key":"ref295","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"ref296","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","volume":"25","author":"Diaconu","year":"2017","journal-title":"Mol Ther"},{"key":"ref297","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol"},{"key":"ref298","doi-asserted-by":"publisher","first-page":"101070","DOI":"10.1016\/j.tranon.2021.101070","volume":"14","author":"Moghanloo","year":"2021","journal-title":"Transl Oncol"},{"key":"ref299","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fphar.2019.00609","volume":"10","author":"Liao","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref300","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jtct.2020.12.026","volume":"27","author":"Skarbnik","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"ref301","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.8010","volume":"34","author":"Mateos","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref302","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11912-020-00983-y","volume":"22","author":"Pant","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"ref303","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3389\/fimmu.2020.01295","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"ref304","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/cancers12020305","volume":"12","author":"Sun","year":"2020","journal-title":"Cancers"},{"key":"ref305","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.2020.38.15_suppl.3030","volume":"38","author":"Patel","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref306","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bbmt.2019.08.009","volume":"26","author":"Lucas","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref307","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"key":"ref308","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1182\/blood-2018-08-864231","volume":"132","author":"Asimakopoulos","year":"2018","journal-title":"Blood"},{"key":"ref309","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"ref310","doi-asserted-by":"publisher","first-page":"575609","DOI":"10.3389\/fimmu.2020.575609","volume":"11","author":"Alfarra","year":"2020","journal-title":"Front Immunol"},{"key":"ref311","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1182\/blood-2020-141623","volume":"136 Supplement 1","author":"Paul","year":"2020","journal-title":"Blood"},{"key":"ref312","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood-2018-99-114960","volume":"132","author":"Cho","year":"2018","journal-title":"Blood"},{"key":"ref313","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1200\/jop.19.00244","volume":"16","author":"Branagan","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"ref314","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/jci126397","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"ref315","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1182\/blood.V130.Suppl_1.505.505","volume":"130","author":"Cohen","year":"2017","journal-title":"Blood"},{"key":"ref316","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"key":"ref317","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"ref318","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1182\/blood-2019-130901","volume":"134","author":"Simoes","year":"2019","journal-title":"Blood"},{"key":"ref319","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"ref320","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"ref321","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/ph14010020","volume":"14","author":"Bonello","year":"2020","journal-title":"Pharmaceuticals"},{"key":"ref322","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/cancers12040988","volume":"12","author":"Holthof","year":"2020","journal-title":"Cancers"},{"key":"ref323","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3389\/fonc.2020.00860","volume":"10","author":"Kostopoulos","year":"2020","journal-title":"Front Oncol"}],"container-title":["ImmunoTargets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=73471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=73471","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T21:01:13Z","timestamp":1673211673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/immunotherapy-of-multiple-myeloma-promise-and-challenges-peer-reviewed-fulltext-article-ITT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":323,"URL":"https:\/\/doi.org\/10.2147\/itt.s306103","relation":{},"ISSN":["2253-1556"],"issn-type":[{"value":"2253-1556","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}